Author

Masahiro Tohkin

Nagoya City University - Cited by 6,553 - Regulatory Science

Biography

Dr.  Masahiro Tohkin  is currently working in Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan. He has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. He has extended his valuable service towards the scientific community with his extensive research work. 
Title
Cited by
Year
Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians
T Hasunuma, M Tohkin, N Kaniwa, IJ Jang, C Yimin, M Kaneko, Y Saito, ...British journal of clinical pharmacology 81 (6), 1078-1090, 2016201
44
2016
Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors
T Sakaeda, S Kobuchi, R Yoshioka, M Haruna, N Takahata, Y Ito, ...International journal of medical sciences 15 (9), 937, 2018201
29
2018
Comparison of the developmental/reproductive toxicity and hepatotoxicity of phthalate esters in rats using an open toxicity data source
K Ambe, Y Sakakibara, A Sakabe, H Makino, T Ochibe, M TohkinThe Journal of Toxicological Sciences 44 (4), 245-255, 2019201
27
2019
In Silico Prediction of Chemical-Induced Hepatocellular Hypertrophy Using Molecular Descriptors
K Ambe, K Ishihara, T Ochibe, K Ohya, S Tamura, K Inoue, M Yoshida, ...Toxicological Sciences 162 (2), 667-675, 2018201
21
2018
Ethnic difference in the pharmacodynamics‐efficacy relationship of dipeptidyl peptidase‐4 inhibitors between Japanese and non‐Japanese patients: a systematic review
Y Ito, K Ambe, M Kobayashi, M TohkinClinical Pharmacology & Therapeutics 102 (4), 701-708, 2017201
19
2017
Pharmacokinetics and pharmacodynamics of meloxicam in East Asian populations: the role of ethnicity on drug response
T Aoyama, Y Ishida, M Kaneko, A Miyamoto, Y Saito, M Tohkin, S Kawai, ...CPT: pharmacometrics & systems pharmacology 6 (12), 823-832, 202
17
2017
Expression, mutation, and methylation of cereblon‐pathway genes at pre‐and post‐lenalidomide treatment in multiple myeloma
T Tachita, S Kinoshita, M Ri, S Aoki, A Asano, T Kanamori, T Yoshida, ...Cancer science 111 (4), 1333-1343, 2020202
17
2020
Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System
A Sanagawa, Y Hotta, T Kataoka, Y Maeda, M Kondo, Y Kawade, ...Cancer Medicine 7 (6), 2269-2279, 2018201
16
2018
Factors affecting drug‐development strategies in Asian global clinical trials for drug approval in Japan
K Asano, Y Uyama, M TohkinClinical and translational science 11 (2), 182-188, 2018201
14
2018
Cross-classification of human urinary lipidome by sex, age, and body mass index
K Okemoto, K Maekawa, Y Tajima, M Tohkin, Y SaitoPLoS One 11 (12), e0168188, 2016201
13
2016
Reconstitution of CYP3A4 active site through assembly of ligand interactions as a grid-template: Solving the modes of the metabolism and inhibition
Y Yamazoe, T Goto, M TohkinDrug Metabolism and Pharmacokinetics 34 (2), 113-5, 2019201
12
2019
Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma
K Maekawa, M Ri, M Nakajima, A Sekine, R Ueda, M Tohkin, N Miyata, ...Cancer Science 110 (10), 3267-3274, 2019201
12
2019
Allopurinol suppresses expression of the regulatory T‐cell migration factors TARC/CCL17 and MDC/CCL22 in HaCaT keratinocytes via restriction of nuclear factor‐κB activation
M Osabe, T Tajika, M TohkinJournal of Applied Toxicology 38 (2), 274-283, 2018201
11
2018
In silico Analysis of Interactions between HLA-B* 58: 01 and Allopurinol-related Compounds
M Osabe, M Tohkin, N HirayamaChem-Bio Informatics Journal 16, 1-4, 2016201
9
2016
Versatile applicability of a grid-based CYP3A4 Template to understand the interacting mechanisms with the small-size ligands; part 3 of CYP3A4 Template study
Y Yamazoe, T Goto, M TohkinDrug Metabolism and Pharmacokinetics 35 (3), 253-265, 2020202
8
2020
Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System
A Sanagawa, Y Hotta, M Kondo, R Nishikawa, M Tohkin, K KimuraAnti-Cancer Drugs 31 (2), 13-19, 2020202
8
2020
Applications of a grid-based CYP3A4 Template system to understand the interacting mechanisms of large-size ligands; part 4 of CYP3A4 Template study
T Goto, Y Yamazoe, M TohkinDrug Metabolism and Pharmacokinetics 35 (6), 45-496, 2020202
8
2020
Solving the interactions of steroidal ligands with CYP3A4 using a grid-base template system
T Goto, M Tohkin, Y YamazoeDrug Metabolism and Pharmacokinetics 34 (6), 351-364, 2019201
7
2019
Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template
Development of template systems for ligand interactions of CYP3A5 and CYP3A and their distinctions from CYP3A4 templateY Yamazoe, M TohkinDrug Metabolism and Pharmacokinetics 38, 10035, 2021202
7
2021
Development of quantitative model of a local lymph node assay for evaluating skin sensitization potency applying machine learning CatBoost
K Ambe, M Suzuki, T Ashikaga, M TohkinRegulatory Toxicology and Pharmacology 125, 105019, 2021202
6
2021

Referred From: https://scholar.google.co.jp/citations?user=fqFw4NIAAAAJ&hl=ja

Cited by
Citations 6553
h-index 35
i10-index 70
Recommended Journals
Open Access Journals